Headquartered in Boston, MA·Fiscal year ends December·NASDAQ: PRAX·praxismedicines.com
About Praxis Precision Medicines
Praxis Precision Medicines is a pre-revenue biopharmaceutical company focused on central nervous system (CNS) disorders. It develops therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, translating insights from genetic epilepsies. Its work runs through two proprietary platforms: the Cerebrum small molecule platform and the Solidus antisense oligonucleotide (ASO) platform. The portfolio spans movement disorders and epilepsy, with four late-stage product candidates.
- **Ulixacaltamide:** a selective T-type calcium channel inhibitor for essential tremor, which affects about seven million U.S. patients. It holds Breakthrough Therapy Designation and its NDA is under FDA review, with a PDUFA date of January 29, 2027.
- **Relutrigine:** a disease state-selective sodium channel modulator for developmental and epileptic encephalopathies. It holds Breakthrough Therapy and Orphan Drug Designations and its NDA for SCN2A and SCN8A DEEs is under FDA review, with a PDUFA date of December 27, 2026.
- **Vormatrigine:** a next-generation sodium channel modulator for adult focal onset seizures and generalized epilepsy, currently in the POWER program.
- **Elsunersen:** an ASO targeting early-seizure-onset SCN2A DEE, developed in collaboration with Ionis Pharmaceuticals and RogCon, now in the registrational EMBRAVE3 trial.
The company is building commercial infrastructure, including sales teams, ahead of potential launches. It is funded by approximately $1.3 billion in cash and investments. Updated
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
Pre-Market Stock Futures: Futures are trading higher this morning, as all the major indices once again closed lower on Tuesday, marking the fourth straight day of losses. The Dow Jones Industrials closed…
Praxis Precision Medicines is a pre-revenue biopharmaceutical company focused on central nervous system (CNS) disorders. It develops therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, translating insights from genetic epilepsies.
What is the PRAX stock price target?
The Wall Street consensus 12-month price target for PRAX is $675.62.